Peptides, corresponding to amino acid sequences in the cytoplasmic domains of the transmembranal glycoproteins encoded by Sindbis and vesicular stomatitis viruses, inhibited release of virus particles and infectious virus when added to infected cells for a 2 h period during a one-cycle growth curve. Each inhibitory peptide was specific for its intended virus. The shortest peptide with antiviral activity for Sindbis virus contained six amino acids, and a related peptide that was acylated at the amino terminus with octanoic acid was ten-fold more potent as an inhibitor. Neither of these peptides affected the synthesis of viral structural proteins, but a third peptide inhibited proteolytic processing of the Sindbis virus E2 glycoprotein. Inhibition of vesicular stomatitis virus particle release was dose-dependent in the range of 50-400 f.Lg mr ' for a peptide corresponding to the G glycoprotein cytoplasmic domain. We postulate that these peptides competitively inhibit attachment of the glycoprotein to intracellular virus structures during assembly of the virion. Thus, drugs, based on peptides that mimic the protein-protein interactions required for virus assembly, may have therapeutic potential.
Introduction
In contrast to many microbial pathogens, viruses contain a limited amount of genetic information and depend on the metabolic activities of their host cells for much of their replication. For this reason, with the exception of vaccines, the development of specific and effective agents to combat viral diseases has been difficult. There are, however, events in the virus replication cycle that are virus specific such as protein-nucleic acid and protein-protein interactions between polypeptides encoded in the viral genome. One example of the latter occurs during the assembly of enveloped viruses when nucleocapslds, consisting of virus nucleoproteins and viral nucleic acids, interact with virus-specific matrix proteins or viral transmembranal glycoproteins at membranes of the infected cell. For the Togaviridae, a family of small, single-stranded RNA enveloped Viruses,assembly initiates when intracellular nucleocapsids bind to cell plasma membranes at site containing the virus glycoproteins (Brown et al., 1972; Garoff and Simons, 1974; Simons and Garoff, 1980) . For the families of orthomyxo-, paramyxo-, and rhabdoviruses, a membrane-associated 'matrix' protein mediates the interaction between glycoproteins and nucleocapsids during virus assembly (Dubois-Dalcq et al., 1984) .
We postulated that short peptides with sequences corresponding to domains critical to these kinds of protein-protein interactions might interfere with virus assembly. There is no structural information currently available about the matrix and nucleocapsid proteins involved in enveloped virus assembly and, in addition, it is likely that their binding sites will contain amino acids that are not contiguous in primary structure. In contrast, the cytoplasmic domains of many Virus transmembranal qlycoproteina are relatively short and their amino acid sequences are known. Furthermore, these portions of the glycoproteins may be conformationally restricted to the cytoplasmic face of the membrane bilayer through ionic interactions with the lipid head groups or by side chain fatty acylation (Capone et al., 1982; Magee et al., 1984; Schlesinger et al., 1981; Rose et aI., 1984) . To test our hypothesis, we synthesized peptides with sequences matching the cytoplasmic domains of virus transmembranal glycoproteins and analysed their effect on virus-infected tissue culture cells. In this report we show that peptides with sequences corresponding to the Sindbis virus E2 glycoprotein and the VSV glycoprotein, G, have virus-specific antiviral activity.
Results

Inhibition of Sindbis virus assembly and release
The Sindbis virus E2 glycoprotein is a transmembranal polypeptide with a 33 amino acid sequence at its carboxyl terminus that is postulated to form the cytoplasmic domain (Schlesinger and Schlesinger, 1986) . Therefore, peptides with sequences correspondin~t~t.h,iS portiO~of the E2 glycoprotein were tested for Inhibition of virus assembly. A 25 amino acid peptide, E2 (391-415), was added to Sindbis virus-infected chicken embryo fibroblasts at 4 h post infection (p.i.), and virus particle secretion was assayed by measuring the amount of 35S-labelled virions released from cells that had been labelled with 35S-methionine from 4.5-6h p.i. In two separate experiments, there was a 50%-70% inhibition of virus particle release from cells treated with the peptide (Table 1) . To determine if a shorter peptide could inhibit virus secretion, thirteen overlapping peptides were synthesized, purified and assayed. Each peptide was tested at least twice. Only four of these were effective at concentrations of 1mg rnr" or less, and three shared portions of the sequence at residues 397-403 of E2 (Table  1 ). The sequence of the smallest inhibitory peptide, E2 (397-402), was LTPYAL. This peptide inhibited Sindbis virus release by 70% ± 6% (n = 4) when tested at 1mg mr' and by 50% at 0.5mg mr' .By modifying this peptide with an amino terminal octanoyl group and an additional alanine at the carboxyl terminus, we obtained a more potent inhibitor. The fatty acylated peptide, E2 (397-403), inhibited Sindbis virus release by 60% at 0.14mg mr' and by 30% at 0.014mg mr".
To ensure that the peptides were affecting release of intracellular virus, we performed control experiments in which the inhibitory peptides were added to Sindbis virus particles aftertheir releasefrom cells. The peptides had no effect on the ability of the released virus to bind to Cellufine.
The peptide E2 (397-402) had little or no effect on intracellular viral protein synthesis, processing of the virus structural proteins and virus nucleocapsid formation (Table2). Similarly, no changes were detected in intracellular virus protein synthesis or glycoprotein processing in the presence of the fatty acylated peptide E2 (397-403). However, the peptide E2 (391-399), which blocked virus release, inhibited the proteolytic conversion of pE2 to E2 (Fig. 1) . The dose response curve for inhibition of virus release by this peptide was roughly equivalent to the level of inhibition of proteolytic processing. The conversion of pE2 to E2 is required for efficient release of the strain of Sindbis virus utilized in this laboratory (Bracha and Schlesinger, 1976) . Peptide E2 (394-413) blocked general viral protein synthesis by an amount equivalent to that shown for inhibition of virus release (data not shown).
In addition to assaying virus particle secretion, we measured the levels of infectious Sindbis virus produced between 4 and 6 h p.i. In three separate experiments, there Was a 50% reduction in virus titre (plaque-forming units) when peptide E2 (397-402) was present at 1mg ml" ( Table 2) .
Inhibition of vesicular stomatitis virus
Peptides corresponding to sequences in the carboxyl terminus of the G glycoprotein of the San Juan strain (Indiana serotype) of vesicular stomatitisvirus (ySV) (Rose and Gallione, 1981) were tested for effects on virus formation. Utilizing an assay similar to that described above, which measures release of 35S-labelled virions from 35S-methionine labelled infected cells, we found that a 29 amino acid peptide with sequences identical to residues 483-511 of the G protein exhibited a dosedependent inhibition of vesicular stomatitis virus release from infected CEF, with maximal effect (90%) at 200 f.Lg 
Specificity of peptides
The anti-Sindbis virus peptides E2 (391-399), E2 (397-402) and octanoylated E2 (397-403) had no effect on VSV
The results described here show that peptides of specific sequence can selectively affect virus replication. The peptides inhibitory for Sindbis virus releasewere clustered around residues 397-403 of the E2 glycoprotein, and we postulate that this short region of the E2 cytoplasmic domain is part of a hydrophobic site recognized by nucleocapsids during their initial binding to the glycoproteins spikes. This short sequence is the most highly conserved part of the cytoplasmic domain in the E2 glycoproteins of 4 different alphaviruses of the Togaviridae (see Table 1 ; Rice and Strauss, 1985; Garoff et al., 1980; Dalgarno et aI., 1983; Kinney et al., 1986; Levinson et al., 1990; Hahn et aI., 1988) . Furthermore, recent data using anti-idiotype antibodies show a complementarity of structure between the E2 cytoplasmic domain and the nucleocapsid of alphaviruses (Vaux et al., 1988) . In addition substitution of phenylalanine for the tyrosine in the cytoplasmic domain of E2 by site-directed mutagenesis of the Sindbis virus genome affects virus assembly. In this mutant the rate of virus release decreased by 70% and the secreted virus particles contain multiple nucleocapsids (Gaedigk-Nitschko and . A limited attempt was made to define a shorter inhibitory sequence in the cytoplasmic domain of VSV G glycoprotein. However, peptides that corresponded to residues 483-488, 490-496, and 496-510 were ineffective in the assays described above. In addition, three peptides with sequences corresponding to residues 489-503, 484-496, and 503-517 in the G glycoprotein of a VSV New Jersey serotype (Gallione and Rose, 1983) were ineffective or toxic to cells infected with the VSV Ogden strain of this latter serotype.
Although we have not determined the precise mechanism of inhibition by the peptides tested here, much of the evidence strongly points to a block at the final stages of virus assembly. Only the Sindbis virus peptide E2 (391-399) blocked a step in the intracellular processing of viral glycoprotein. The putative site where these peptides act is Discussion (San Juan strain) particle formation, and the VSV peptide, G (483-511), had no effect on Sindbis virus (fable 3). We have described elsewhere (Collier et al., 1991 ) that a 10-amino acid peptide corresponding to the influenza virus haemagglutinin did not affect Sindbis virus particle release.Thus, not only were the peptides virus specific but the peptide concentration that blocked virus release had little or no effect on those general cellular metabolic activities needed for virus replication. In addition, with the exceptions of E2 (391-399) and E2 (394-413) noted above, none of the inhibitory peptides produced significant changes in the pattern of intracellular virus-specific proteins (data not shown). Fig. 1(a) . Inhibition of Sindbis virus formation and proteolytic conversion of pE2 to E2 by the peptide E2 (391-399); (a) Measurement of virus particle release, infectious virus formation, and proteolytic processing of pE2 to E2 from cells, and (b) SOS-PAGE analysis of the 35S-methionine labelled cell extract and released virions. Peptide E2 (391-399) was dissolved directly into medium lacking methionine (3.9mg in OAml medium and 1 /-1-1 of 0.5M sodium carbonate was added to neutralize the acidic solution) and added to Sindbis virus infected CEF at 4 h p.i. 35S-Methionine was added 30 min later and at 6h p.i., cells and secreted virus were collected. Proteins were analysed by SOS/PAGE. Identical results were obtained when the peptide at 1 mg rnr' was first dissolved in eTAS. For measuring inhibition of particle formation, (-.-), the protein bands corresponding to the glycoproteins pE2, E1, and E2, and the capsid protein were excised from polyacrylamide gels after SQS/ PAGE and their levels of radioactivity quantitated. Infectious virus formation (--0--) was measured by plaque titration. Inhibition of the conversion of pE2 to E2 (--f\.--) was calculated from the ratio of the amount of radioactivity incorporated into the bands corresponding to the two proteins. Virus specific proteins are noted. The results of one experiment are shown. mr ' peptide and a half-maximal value of about 50 fL9 mr ' (Fig. 2) . Assays for infectious virus by plaque titration showed a log reduction in virus titre in cells treated with 200 fL9 rnl" of the peptide (Fig. 2) . C To obtain nucleocapsids, infected cells that had been labelled with 35S-methionine between 4.5 and 6h p.i. were lysed in 50mMTris, pH 7.5, 100mM NaCI, 1 mM EDTA, (TNE), containing 0.5% TritonX-100 and 0.5% 1,5-napthalenedisulphonate. Insoluble material was removed by centrifugation in a microfuge for 5 min. Approximately 60% of the supernatant was applied to a 15-30% sucrose density gradient in TNE containing 0.05% Triton X-100, 0.05% 1,5-naphthalenedisulphonate and 5 flog mr ' bovine serum albumin. After centrifugation at 30000 rpm for 2h in a Beckman SW 41 rotor, the gradients were fractionated and aliquots subjected to analysis by SDS-PAGE. The amount of capsid protein in the peak fraction of nucleocapsid was quantitated by scintillation counting of the gel band. in the cell's cytoplasm, specifically at the cytoplasmic face of the plasma membrane. However, the peptides were added to the extracellular medium and they would have to penetrate the lipid bilayer in order to function. A mechanism for delivery of peptides to the cell cytoplasm from the extracellular fluid has not been described although transport of many small compounds such as ions, amino acids, and sugars across cell membranes occurs via specific channels or pores (review in Gennis, 1990) . One possible pathway for transport of small peptides and some proteins 
Materials and Experimental procedures
Materials across a lipid bilayer may involve proteins related to ATP-binding cassette (ABC) superfamily of transporter proteins (Higgins et aI., 1990) . Most of the peptides tested here were solubilized with small amounts of detergent or organic solvents and their permeability could be facilitated by these lipid soluble materials. The enhanced ability of the octanoylated peptide E2 (397-403) to inhibit Sindbis virus release may be due to an increase in transport and/or partitioning of this more lipophilic peptide in the membrane. The peptides described here were specific inhibitors of their target virus when added during a one-cycle growth curve. A previous study (Richardson et aI., 1980; Richardson et aI., 1981) described short hydrophobic peptides that inhibited the growth of paromyxo-and myxo-viruses. These peptides had sequences corresponding to the amino terminus of the viral glycoproteins that function as fusoqens, More recently, these kinds of peptides were found to be non-specific inhibitors of membrane fusion (Kelsey et aI., 1990) .
Our data show that replication of two enveloped viruses with different assembly mechanisms could be inhibited selectively by peptides based on a common type of virus protein-protein interation and suggest that other kinds of enveloped viruses might be susceptible to similar kinds of peptides. Appropriate modifications or design of compounds based on these peptides might ultimately lead to potent antiviral agents.
Peptides were synthesized by standard solid-phase techniques using t-butyloxycarbonyl chemistry and were cleaved from the a Peptides were added at the indicated concentrations to CEF infected with either Sindbis or vesicular stomatitis virus at 4 h p.i. followed 30 min later by addition of 35S-methionine. At 6h p.i., infected cells and secreted virions were collected and radio-labelled proteins separated by SOS/PAGE. The amounts of radioactivity in the proteins were determined by excising the protein bands and counting them in a scintillation counter. Inhibition is the reduction in the amounts of protein released as virions from cells treated with the peptide compared to cells treated only with the detergent and no peptide. b Peptide contained an octanoylated amino terminus. support with anhydrous hydrofluoric acid. All peptides were purified by reverse phase high performance liquid chromatography (HPLC) and their composition verified by amino acid analysis and, in some cases, by mass spectrometry. The sequences were based on published data for Sindbis virus E2 (Strauss etal.,1984) and vesicular stomatitis virus (Rose and Gallione, 1981) . The names of the peptides represent the protein and residue numbers in the intact protein sequence from where the sequence of the peptide was derived; i.e, the peptide corresponding to residues 391-396 of the E2 protein of Sindb is virus is named E2 (391-396).
Most of the peptides required small amounts of detergent cetyl trimethylammonium bromide (CTAB), or organic solvent (DMSO) to be solubilized (see below). Plaquing of Sindbis virus and vesicular stomatitis virus was performed on secondary chicken embryo fibroblasts (CEF) that were grown in 6-well tissue culture dishes with Earle's minimal essential medium (MEM) containing 3% fetal bovine serum (FBS), as described by Pfefferkorn and Hunter (1963) . Cells were infected with virus in 0.2 ml of phosphate-buffered saline solution containing 1% FBS. The monolayers were overlaid with MEM containing 1% agarose and 1% FBS. Plaques were visualized with 1% crystal violet in 50% ethanol after 1-2 days growth at 37°C.
Assay for virus growth and release
Secondary cultures of chicken embryo fibroblasts were routinely used as host cells for virus infection as many different types of viruses grow rapidly and produce high titres in cultures of these cells. Cells were grown to confluency in Earle's MEM with 3% FBS in 6-well tissue culture dishes and infected with Sindbis virus or vesicular stomatitis virus at a multiplicity of infection of 5. Virus was added to cells in 0.2 ml of a phosphate-buffered saline (PBS) solution containing 1% FBS and 1 h later 2 ml of complete medium was added. This medium was replaced 3 h later with medium lacking L-methionine and containing.various amounts of peptide. Solutions of the peptides were prepared by adding 4-6 fLl of 0.001 % CTAB or DMSO to 1 mg of peptide followed by Peptide inhibition of enveloped virus release 35 100-200 fLl of PBS or medium lacking methionine. No inhibition of cell growth or virus replication was detected in control cell cultures that received equivalent amounts of CTAB or DMSO alone. The peptide solutions were mixed immediately prior to adding them to 1 ml of culture medium. After 0.5 h, 35S-L-methionine (Amersham, Arlington Heights, IL, USA, 1500Ci rnmol") was added to each well to a final concentration of 10 p.Cimr "and an equivalent amount added 0.75h later. After another 0.75h the culture fluid was collected and the cell monolayers washed three times with 1 ml of cold PBS. The monolayer was scraped into PBS and the cells pelleted by centrifugation in a microfuge for 10 min. The cell pellet was dissolved in SDS sample buffer (Laemmli, 1970) . The washes were combined with the culture fluid and centrifuged briefly at 2000 rpm to remove any cellular debris. For collecting extracellular Sindbis virus, a 0.4 ml solution of Cellufine (Amicon, Beverly, MA, USA), 10% vlv in PBS, was added to the supernatant and incubated at 23°C for 1 h (Gaedigk-Nitschko and . Sindbis virus was quantitatively bound to this resin under the conditions described. The Cellufine was pelleted by brief centrifugation, washed with PBS once and the bound virus proteins released by boiling in SDS-gel sample buffer. Extracellular VSV was obtained by centrifugation of the medium and washes at 40000 rpm for 1 h in a Beckman type 65 rotor in the presence of unlabelled VSV carrier, and the pellets were solubilized with SDS sample buffer. Viral proteins from the cell and the extracellular virus were separated by SDS-PAGE employing 11% acrylamide gels and the gels treated with PPO (Bonner and Laskey, 1974) . Protein bands corresponding to the virus specific structural proteins (pE2, E1, E2, and Capsid for Sindbis virus and G, N, and M proteins for VSV) were identified by fluorography, excised from the dried gel, and radioactivity measured by liquid scintillation counting. This procedure is accurate to 5% (Schlesinger and Malfer, 1982) .
